Orthofix Medical Inc. (OFIX) Stock Price & Analysis
Orthofix Medical Inc. (OFIX) rose 1.86% to USD 9.87 as of June 10, 2026 at 02:25 UTC, according to Nexqual real-time market data.
OFIX last closed at USD 9.69; the session ranged USD 9.64–10.03 on volume of 501,046 shares. Market capitalization is $398.96M, with a 52-week range of USD 9.13–16.99 (NMS). Source: Nexqual, June 10, 2026 at 02:25 UTC.
Key Statistics (as of June 10, 2026 at 02:25 UTC)
| Price | USD 9.87 |
|---|---|
| Change | ▲ 1.86% (up) |
| Previous Close | USD 9.69 |
| Open | USD 9.72 |
| Day Range | USD 9.64 – 10.03 |
| 52-Week Range | USD 9.13 – 16.99 |
| Volume | 501,046 shares |
| Market Cap | $398.96M |
| Exchange | NMS |
Technical Analysis (OFIX)
Nexqual's technical model rates OFIX "STRONG SELL" based on 0 bullish and 5 bearish signals across 124 daily candles, as of June 10, 2026 at 02:25 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 39.65 (neutral) |
| vs SMA50 | Below (USD 11.51) |
| MACD | -0.57 (negative) |
Analyst Ratings (OFIX)
Wall Street analysts rate OFIX "None" based on 4 analysts, with a mean price target of USD 15 (range USD 12–18), per Nexqual as of June 10, 2026 at 02:25 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 4 |
| Mean Target | USD 15 |
| High Target | USD 18 |
| Low Target | USD 12 |
| Buy / Hold / Sell | 3 / 2 / 0 |
Earnings (OFIX)
| Next Earnings Date | 2026-08-04 |
|---|---|
| EPS Estimate | USD -0.03 |
| Revenue Estimate | $209.28M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.11 vs est -0.29 ▲ beat |
| 2025-12-31 | USD 0.24 vs est 0.42 ▼ miss |
| 2025-09-30 | USD 0.2 vs est 0.12 ▲ beat |
| 2025-06-30 | USD 0.13 vs est 0.04 ▲ beat |
Source: Nexqual, June 10, 2026 at 02:25 UTC.
Financials & Fundamentals (OFIX)
| Total Revenue | $825.37M |
|---|---|
| Revenue Growth (YoY) | +1.60% |
| Gross Margin | +71.01% |
| Operating Margin | -6.75% |
| Profit Margin | -7.27% |
| ROE | -13.43% |
| Debt / Equity | 60.26 |
| Current Ratio | 2.87 |
| Total Cash | $120.28M |
| Total Debt | $262.26M |
| Free Cash Flow | $22.02M |
Source: Nexqual, June 10, 2026 at 02:25 UTC.
Financial Health Score (OFIX)
Nexqual rates Orthofix Medical Inc.'s overall financial health "Mixed" across five dimensions, as of June 10, 2026 at 02:25 UTC.
| Growth | Mixed — Revenue +2.9% YoY (annual), slow |
|---|---|
| Profitability | Solid — Gross margin 71%, operating -7% |
| Balance Sheet | Strong — $120M cash vs $262M debt |
| Cash Flow | Mixed — FCF $22M, slim 2.7% margin |
| Efficiency | Critical — ROE -13%, ROA -3.3% |
Ownership (OFIX)
| Insider Ownership | +1.86% |
|---|---|
| Institutional Ownership | +92.04% |
| Shares Outstanding | 40.42M |
| Float | 40.10M |
| Short % of Float | +5.46% |
Source: Nexqual, June 10, 2026 at 02:25 UTC.
Leadership (OFIX)
Orthofix Medical Inc. is led by Massimo Calafiore (age 53), President, CEO & Director, per Nexqual as of June 10, 2026 at 02:25 UTC.
| President, CEO & Director | Massimo Calafiore (age 53) |
|---|---|
| Chief Financial Officer | Julie B. Andrews (age 54) |
| President of Global Operations & Quality | Aviva McPherron (age 48) |
| President of Global Biologics & Limb Reconstruction | Patrick Fisher (age 51) |
Major Backers & Investors (OFIX)
Notable institutional backers of Orthofix Medical Inc. include Engine Capital Management, LP, Juniper Investment Company, LLC, Rubric Capital Management LP, according to Nexqual as of June 10, 2026 at 02:25 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Engine Capital Management, LP | 10.86% |
| Juniper Investment Company, LLC | 9.84% |
| Rubric Capital Management LP | 9.21% |
| Paradigm Capital Management | 8.18% |
| Armistice Capital, LLC | 6.68% |
| Millennium Management | 2.64% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 11.05% |
| Vanguard Group | 8.59% |
| Geode Capital | 2.32% |
| State Street | 2.24% |
Source: Nexqual, June 10, 2026 at 02:25 UTC.
From Orthofix Medical Inc.'s Latest SEC 10-K Filing (filed 2026-02-24)
Key Strengths & Strategy (as disclosed to the SEC)
- Orthofix Medical Inc., together with its subsidiaries, operates as a medical technology company in the United States, Italy, the United Kingdom, France, Germany, Brazil, and internationally.
- It operates through two segments, Global Spine and Global Limb Reconstruction.
- This segment also designs, develops, and markets a portfolio of navigation technologies, including tracked surgical tools, intelligent software, and imaging equipment based on machine-vision and optical innovations; and 7D FLASH Navigation System, a navigation platform for spinal and cranial procedures.
- The Global Limb Reconstruction segment offers products and solutions for the underserved limb reconstruction market, including deformity correction, limb lengthening, complex fracture management, and limb preservation.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| CNMD | CONMED Corporation | USD 36.9 | ▲ 4.95% |
| MMSI | Merit Medical Systems, Inc. | USD 67.51 | ▲ 4.7% |
| ICUI | ICU Medical, Inc. | USD 142 | ▲ 3.95% |
| IART | Integra LifeSciences Holdings C | USD 17.9 | ▲ 5.36% |
| ATRC | AtriCure, Inc. | USD 27.3 | ▲ 0.74% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 02:25 UTC. This page is informational and not investment advice.